An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist

The purpose of this study is to evaluate if the study drug is safe and well-tolerated. This research study is a first-in-human study. This means that if you participate in this study, you will be one of the first people to receive DPTX3186. The study drug, DPTX3186, is an investigational drug which means it is not approved by any country, including in the United States by the Food and Drug Administration (FDA). DPTX3186 is a small drug-like compound created to target special areas inside cells called condensates. Condensates are compartments inside cells that don't have membranes. They contain molecules that help control important activities within the cell. When condensates don't work correctly, it can lead to diseases like cancer, including stomach cancer. Condensates can be repaired as a result of study drug treatment

Are you Eligible? (Inclusion Criteria)

• Adult men and women ≥18 years of age. If 18 years is not the age of majority, then adult men and women ≥ age of majority per local regulation. 2. Signed and dated informed consent in a format approved by the ethics committee must be obtained prior to any procedures unless considered standard of care. 3. Subjects must be willing and able to comply with the protocol for the duration of the study including planned treatments, scheduled visits, and monitoring procedures, and including EOT, Safety follow-up visit and Survival follow-up assessment.